Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBayer’s Novel Anti-Cancer Compound Regorafenib Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
BayNews International, 09/23/09
Bayer Schering Pharma AG, Germany, announced results from a Phase II trial of regorafenib, a potent oral multi–kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma. These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
BMC Infectious Diseases, 12/03/09
Sponsor
Article Search
Sponsor